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PREAMBLE
This practice guideline has been approved by the
American Association for the Study of Liver Diseases
and the American Society of Transplantation. These
recommendations provide a data-supported approach
to management of adult patients who have success-
fully undergone liver transplantation. They are based
on the following: (1) a formal review and analysis of
recently published world literature on the topic (via a
MEDLINE search); (2) A Manual for Assessing Health
Practices and Designing Practice Guidelines (American
College of Physicians)1; (3) guideline policies,2 includ-
ing the American Association for the Study of Liver
Diseases policy on the development and use of prac-
tice guidelines and the American Gastroenterological
Association policy statement on guidelines3; and (4)
the experience of the authors in the specified topic.
Intended for use by physicians and health care pro-
viders workingwith adult recipients of liver transplanta-
tion (LT), these recommendations suggest preferred
approaches to the diagnostic, therapeutic, and preven-
tive aspects of care. They are intended to be flexible, in
contrast to standards of care, which are inflexible poli-
cies to be followed in every case. Specific recommenda-
tions are based on relevant published information.
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To more fully characterize the available evidence
supporting the recommendations, the American Asso-
ciation for the Study of Liver Diseases Practice Guide-
lines Committee has adopted the classification used
by the Grading of Recommendations Assessment, De-
velopment, and Evaluation (GRADE) workgroup with
minor modifications (Table 1).4 In the GRADE system,
the strength of a recommendation is classified as (1)
strong or (2) weak. The quality of evidence supporting
a strong or weak recommendation is designated by 1
of 3 levels: (A) high, (B) moderate, or (C) low.
LT AS A TREATMENT FOR END-STAGE
LIVER DISEASE
LT is the treatment of choice for patients with decom-
pensated cirrhosis, acute liver failure, small hepato-
cellular carcinomas (HCCs), or acute liver failure. The
success of LT has meant that there is a growing
cohort of LT recipients throughout the world. From
1985 through 2011, approximately 100,000 persons
in the United States underwent LT. On December 30,
2011, there were 30,000 LT recipients who were alive
and had survived at least 5 years, and there were
more than 16,000 recipients with 10 or more years’
survival. These long-term survivors are at risk of early
death and increased morbidity. The purpose of this
guideline is to assist in the management of adult
recipients of LT, identify the barriers to maintaining
their health, and make recommendations on the ways
to best prevent or ameliorate these barriers. This
guideline focuses on management beyond the first 90
days after transplantation.
MORTALITY AFTER LT
The greatest proportion of deaths or retransplants af-
ter LT occur soon after transplantation. The causes of
death and graft loss vary according to the interval
from transplantation, with infection and intraopera-
tive and perioperative causes accounting for nearly
60% of deaths and graft losses in the first posttrans-
plant year. After the first year, death due to acute
infections declines, whereas malignancies and cardio-
vascular causes account for a greater proportion of
deaths. The recurrence of the pretransplant condition,
especially hepatitis C virus (HCV) or autoimmune liver
disease, is an increasingly important cause of graft
loss the longer the patient survives transplantation
for these etiologies. Today, death (or a need for
retransplantation) attributable to acute or chronic al-
lograft rejection is uncommon throughout the first 10
years after transplantation.
MORBIDITY AFTER LT
The transplanted liver becomes partially tolerant of
immune-mediated injury, so the requirement for
immunosuppression declines after the first 90 days.
Although some LT recipients may eventually achieve
operational tolerance (ie, maintenance without immu-
nosuppressant medications), this is rare. Most
patients receive immunosuppression throughout the
life of the allograft.5 The continued use of immuno-
suppression carries inevitable consequences: an
increased risk of bacterial, viral, and fungal infec-
tions, which can be recurrent or newly acquired; met-
abolic complications such as hypertension, diabetes
mellitus (DM), hyperlipidemia, obesity, and gout; and
hepatobiliary or extrahepatic de novo cancers [includ-
ing posttransplant lymphoproliferative disorder
(PTLD)]. The combination of the complications of
immunosuppression and the recurrence of the under-
lying liver disease translates into a heavy burden of ill
heath for many LT recipients. An analysis of a longi-
tudinal US database of 36,847 LT recipients indicated
that the prevalence of kidney failure [defined as a glo-
merular filtration rate of 29 mL/minute/1.73 m2 of
body surface area or less or the development of end-
stage renal disease (ESRD)] was 18% at 5 years and
25% at 10 years.6 LT recipients have at-risk cardio-
vascular profiles with a high prevalence of hyperten-
sion requiring antihypertensive medications, recur-
rent DM and new-onset diabetes mellitus (NODM),
and hyperlipidemia requiring lipid-lowering agents.
Cardiovascular disease and renal failure are the
leading nonhepatic causes of morbidity and mortality
late after LT (Table 2). The recurrence of the original
disease, such as a chronic HCV infection, primary
TABLE 1. GRADE
Strength of Recommendation Criteria
1. Strong Factors influencing the strength of the recommendation include the quality
of the evidence, the presumed patient-important outcomes, and the cost.
2. Weak There is variability in the preferences and values or more uncertainty.
The recommendation is made with less certainty, or the cost or resource
consumption is higher.
Quality of Evidence Criteria
A. High Further research is unlikely to change confidence in the estimate of the clinical effect.
B. Moderate Further research may change confidence in the estimate of the clinical effect.
C. Low Further research is very likely to affect confidence in the estimate of the clinical effect.
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biliary cirrhosis (PBC), primary sclerosing cholangitis
(PSC), autoimmune hepatitis (AIH), or HCC, can cause
ongoing morbidity and mortality. Many of the patients
undergoing LT have a past or present history of addic-
tions, especially to alcohol, cigarettes, or both, which
may also persist with harmful effects on patients’
health, often by interacting with other risk factors al-
ready mentioned.
An assessment of the quality of life after LT has
shown that although quality measures improve in LT
patients in most domains in comparison with their
status before transplantation, LT recipients continue
to have many deficits in comparison with age-
matched control populations; these are manifested as
worsening physical symptoms, fatigue, and a greater
sense of being unwell.7
Through the reduction of cardiovascular risks, the
suppression or eradication of specific infections,
improved surveillance for cancer, and the prevention
or treatment of recurrent liver diseases, both the
quantity and the quality of post-LT life can be
improved. In these guidelines, we show how a concen-
trated effort to moderate immunosuppression, man-
age recurrent disease, and ameliorate metabolic com-
plications of immunosuppression is required to
convert short-term success into sustained success for
an extended healthy life.
COMPLICATIONS OF PORTAL
HYPERTENSION AFTER LT
Typically, clinical features of liver failure and portal
hypertension resolve rapidly after LT, and they are
not usual after the first 3 months. The exception is
splenomegaly, which may persist for years. Variceal
hemorrhage is very unusual unless the patient has an
occluded portal vein. The late emergence of hepatic
encephalopathy in a patient with a functioning liver
allograft suggests the development of clandestine cir-
rhosis or a persistent portosystemic shunt. Late-onset
ascites or peripheral edema may indicate stenosis of
the inferior vena cava or portal vein anastomosis. Per-
sistent late ascites in a patient with a recurrent HCV
infection is a poor prognostic sign.
LIVER TESTS
Liver tests are routinely monitored after LT. When
liver tests are elevated for a healthy recipient, the
course of action will depend on the severity and type
of abnormality (cholestatic, hepatitic, or other). Clini-
cal challenges arise when liver tests are normal in the
presence of graft damage or conversely abnormal in
an asymptomatic LT recipient. The many causes of
liver test abnormalities in the asymptomatic recipient
are shown in Table 3. More than 1 cause may coexist
in the same patient. When abnormal liver tests are
recognized in a healthy, asymptomatic LT recipient, it
is reasonable to repeat the tests in 1 to 2 weeks. A de-
cision to investigate further should be based on the
persistence and severity of the liver test abnormal-
ities. Investigations should include a thorough history
and examination, appropriate laboratory tests, and
Doppler ultrasound of the liver. It should not be
assumed without appropriate histological confirma-
tion that abnormal liver tests represent immune-
mediated damage.
Elevated alkaline phosphatase, total bilirubin, and
aminotransferase levels may arise from the late
appearance of biliary anastomotic strictures due to
TABLE 2. Prevalence of Cardiovascular Risk Factors
and CKD in LT Recipients Beyond the First
Posttransplant Year
Prevalence Rate
Cardiovascular risk factor
Metabolic syndrome* 50%-60%
Systemic hypertension 40%-85%
DM 10%-64%
Obesity 24%-64%
Dyslipidemia 40%-66%
Cigarette smoking 10%-40%
CKD (stage 3-4)† 30%-80%
End-stage kidney disease 5%-8%
*Any 3 of the following: hypertension, obesity, dyslipidemia,
and DM.
†Estimated glomerular filtration rate ¼ 15 to <60 mL/
minute/1.73 m2.
TABLE 3. Causes of Liver Test Abnormalities in the
Asymptomatic Recipient
Allograft parenchymal damage
Immune-mediated disease (rejection and de novo
AIH)
Recurrent disease (HCV, HBV, PBC, PSC, AIH, and
others)
Drug toxicity (including immunosuppressive drugs)
Alcohol and other toxins
De novo infection (including de novo HBV and
HCV)
Space-occupying lesion (recurrent cancer)
De novo or recurrent NAFLD
Biliary damage
Biliary strictures (anastomotic strictures, hepatic
artery thrombosis or stenosis, and others)
Biliary stones/cast syndrome
Recurrent PSC
Vascular disease
Hepatic artery thrombosis
Portal or hepatic vein thrombosis
Metabolic disease in the allograft
Gilbert’s syndrome
Nonhepatic disease mimicking liver disease
Hemolysis causing raised indirect bilirubin levels
Bone disease causing raised alkaline phosphatase
levels
Nonhepatic disease causing liver abnormalities
Celiac disease
Diabetes
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thrombosis or stenosis of the hepatic artery or to
recurrent PSC or PBC. Appropriate biliary imaging
includes endoscopic retrograde cholangiopancreatog-
raphy, magnetic resonance cholangiopancreatogra-
phy, and/or ultrasound. Biliary cast syndrome refers
to a severe form of intrahepatic bile duct ischemic
injury unique to post-LT patients,8 and it is associ-
ated with hepatic artery thrombosis and the use of a
split liver, including partial grafts derived from living
donors and, more commonly, from donation after car-
diac death donors. Biliary cast syndrome may resolve
with repeated clearance of bile duct debris either per-
cutaneously or endoscopically.
Recommendations
1. The frequency of monitoring with liver tests
should be individualized by the transplant center
according to the time from LT, the complications
from LT, the stability of serial test results, and
the underlying cause (grade 1, level A).
2. Depending on the pattern of liver tests, magnetic
resonance imaging, computed tomography, endo-
scopic retrograde cholangiopancreatography, and
sonography may be appropriate (grade 1, level A).
3. Liver histology should be obtained when paren-
chymal injury is suspected as the cause of
abnormal liver tests (grade 1, level A).
VASCULAR THROMBOSIS
Hepatic artery thrombosis (HAT) or stenosis may pres-
ent clinically after 3 months, as :
• intrahepatic non-anastomotic strictures and/or
sterile or infected fluid collections within the liver,
sometimes referred to as bilomas,
• ischemic cholangiopathy or
• biliary cast syndrome.
The combination of hepatic artery thrombosis and
biliary complications usually requires retransplanta-
tion.9
Recommendations
4. Bilomas and biliary cast syndrome should be
managed in a center with expertise in LT medi-
cine, radiology, and biliary endoscopy (grade 1,
level A).
5. Hepatic artery thrombosis or stenosis is most
readily assessed initially by Doppler ultrasound,
but angiography is usually required to confirm
the diagnosis and plan therapy (grade 1, level B).
IMMUNOSUPPRESSION
The choice of immunosuppression depends on the
following:
• Indication for transplantation: the choice of
immunosuppression may affect disease recur-
rence (eg, HCV, malignancy, or autoimmune
disease).
• Comorbidities.
• Drug side effects: calcineurin inhibitors (CNIs)
may cause renal impairment.
• Likelihood of pregnancy: mycophenolate and
mammalian target of rapamycin (mTOR) inhibi-
tors such as sirolimus are potential teratogens.
• History of severe or recurrent rejection.
• Prior experience with the various immunosup-
pressive agents.
• History of or risk for cancers.
• History of or risk for infections.
There is no reliable marker for determining the
effective level of immunosuppression; therefore, the
choice of the agent (or agents) and doses given will be
determined by the clinical, laboratory, and histologi-
cal response. The CNI dose is generally determined by
the drug level; the target levels after 3 months are 5
to 10 ng/mL for tacrolimus and 100 to 150 ng/mL for
cyclosporine (both are whole blood trough levels). The
target whole blood trough level for sirolimus is 5 ng/
mL. The need for therapeutic drug monitoring for
mycophenolate is uncertain. Table 4 describes drug-
TABLE 4. Major Drug-Drug Interactions Involving Immunosuppressive Agents
Antimicrobials CNIs mTOR Inhibitors Mycophenolate
Fluoroquinolones (primarily
ofloxacin > ciprofloxacin)
Increased levels
Macrolides (erythromycin >
clarithromycin > azithromycin)
Markedly
increased levels
Markedly
increased levels
Rifamycins (rifampin > rifabutin) Markedly
decreased levels
Markedly
decreased levels
Linezolid Increased
myelosuppression
Increased myelosuppression
and platelet decrease
Triazoles (ketoconazole/
voriconazole/posaconazole >
itraconazole/fluconazole)
Increased levels Increased levels
(voriconazole
contraindicated)
Ganciclovir/valganciclovir Increased
myelosuppression
Increased myelosuppression
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drug interactions involving the commonly used immu-
nosuppressant medications. Common side effects of
immunosuppressants are presented in Table 5.
The majority of LT recipients need lifelong immuno-
suppression to maintain graft function. A very small
number of LT recipients develop operational tolerance
to the allograft and do not require long-term
immunosuppression.5
LATE REJECTION
Late rejection is defined as rejection that has its onset
more than 90 days after transplantation. Tradition-
ally, 2 forms have been recognized: cellular rejection
(also known as acute cellular rejection and late-onset
rejection) and ductopenic rejection (also known as
vanishing bile duct syndrome). Both forms of rejection
are, until the late stages, asymptomatic, and the diag-
nosis is made through the investigation of abnormal
liver tests; the diagnosis can be confirmed only on the
basis of histology. For both cellular rejection and duc-
topenic rejection, the Banff criteria have been adopted
to define the nature and severity.10 Liver tests in
patients with late-onset cellular rejection show non-
specific abnormalities with a rise in serum bilirubin
and aminotransferases. Histologically, cellular rejec-
tion is characterized by the triad of inflammatory bile
duct damage, subendothelial inflammation of the por-
tal, central, or perivenular veins, and a predominantly
lymphocytic portal inflammatory infiltrate with neu-
trophils and eosinophils in addition. The focus of
inflammation may be portal, central, or both, but the
central component is more prominent and frequently
occurs as pure centrilobular necroinflammation (iso-
lated central perivenulitis). Late acute rejection differs
from early acute cellular rejection by having fewer
classic histological features.
Risk factors leading to late-onset cellular rejection
include the following:
• Reduction of immunosuppression (whether iatro-
genic or due to noncompliance).
• Pre-LT autoimmune liver disease.
• Concurrent administration of interferon (for HCV
treatment).
The differential diagnosis includes infection, recur-
rent and de novo autoimmune disease, and drug tox-
icity; it may sometimes be difficult to distinguish cel-
lular rejection from HCV infection, and indeed, the
two often coexist.
In mild cases of cellular rejection, an increase in
maintenance levels of immunosuppression may be
sufficient, whereas in histologically moderate or
severe cases, the treatment should be a short course
of increased immunosuppression (eg, methyl predni-
sone at 500 mg/day or prednisolone at 200 mg/day
for 3 days) followed by an increase in the baseline
immunosuppression. A full response (defined as a
return to normal liver tests) is seen in only approxi-
mately half of patients, with approximately 25% devel-
oping a further episode of cellular rejection and 25%
developing ductopenic rejection.
Ductopenic rejection is seen most commonly in the
first year but may occur at any time. Recent data sug-
gest that humoral alloreactivity mediated by antibodies
against donor human leukocyte antigen (HLA) mole-
cules, acting in concert with cellular mechanisms, may
play a role in the development of ductopenia (a process
known as antibody-mediated rejection).11 The onset of
ductopenia is usually insidious, with a progressive rise
in liver tests with a cholestatic picture (a rise in alka-
line phosphatase and gamma-glutamyl transpeptidase
followed by a progressive rise in serum bilirubin). In
late cases, the recipient may complain of pruritus and
jaundice. A liver biopsy sample with at least 10 portal
tracts is advisable in order to establish with confidence
that injury to and loss of bile ducts have occurred. In
the early stages of ductopenic rejection, there may be a
cellular infiltrate, but more commonly, the characteris-
tic features include the progressive loss of bile ducts
from the portal tracts and cholestasis; in late stages,
foamy macrophages may be seen.
Risk factors for ductopenic rejection include the
following:
• Recurrent and unresponsive cellular rejection.
• Transplantation for autoimmune disease.
• Exposure to interferon.
• Loss of a previous graft to ductopenic rejection.
The differential diagnosis includes recurrent disease
(PBC or PSC) and drug toxicity.
The treatment of ductopenic rejection is increased
immunosuppression, and an increase in or switch to
tacrolimus may be effective in some early cases.
TABLE 5. Unwanted Side Effects of Immunosuppressives
Side Effect Corticosteroids CNIs mTOR Inhibitors Mycophenolate Mofetil
Kidney injury  þþþ þ (proteinuria) 
Bone disease þþþ   
Gastrointestinal þ/   þ
Bone marrow suppression    þ
Pulmonary fibrosis   þ 
Hypercholesterolemia þ þ þþþ 
Diabetes þþ þ (tacrolimus)  
Hypertension þ þþ þ 
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Conversely, especially when fewer than 50% of the
portal tracts contain bile ducts, the condition pro-
gresses to graft failure.
Recommendations
6. Immunosuppressive drugs for LT recipients
should be prescribed and monitored only by
those with knowledge and expertise in that area.
The choice of agents will depend on many fac-
tors, and no one regimen can be recommended
for any patient (grade 2, level A).
7. Every patient’s immunosuppressive regimen
should be reviewed at least every 6 months and
modified as required with the goal of minimizing
long-term toxicities (grade 1, level B).
8. Rejection can be reliably diagnosed only on the ba-
sis of liver histology; a biopsy sample should be
taken before treatment initiation and classified
according to the Banff criteria (grade 1, level A).
9. Although the long-term withdrawal of all immu-
nosuppression can be achieved in a small num-
ber of patients, this should be undertaken only
with select recipients and under close supervi-
sion (grade 2, level C).
PROMOTING HEALTH AFTER LT
Recommendations
10. Frequent handwashing reduces the risk of
infection with pathogens acquired by direct
contact, including Clostridium difficile, commu-
nity-acquired viral infections, and pathogens
found in soil (grade 1, level A).
11. Shoes, socks, long-sleeve shirts, and long pants
should be worn for activities that will involve soil
exposure and tick exposure and also to avoid
unnecessary sun exposure (grade 1, level A).
12. During periods of maximal immunosuppres-
sion, LT recipients should avoid crowds to min-
imize exposures to respiratory illnesses (grade
1, level A).
13. Work in high-risk areas, such as construction,
animal care settings, gardening, landscaping,
and farming, should be reviewed with the
transplant team to develop appropriate strat-
egies for the prevention of high-risk exposures
(grade 2, level A).
14. LT recipients should avoid the consumption of
water from lakes and rivers (grade 1, level A).
15. LT recipients should avoid unpasteurized milk
products and raw and undercooked eggs and
meats (particularly uncooked pork, poultry,
fish, and seafood; grade 1, level A).
16. LT recipients should avoid high-risk pets,
which include rodents, reptiles, chicks, duck-
lings, and birds (grade 1, level A).
17. Travel by LT recipients, especially to developing
countries, should be reviewed with the trans-
plant team aminimum of 2 months before depar-
ture to determine optimal strategies for the
reduction of travel-related risks (grade 1, level A).
18. LT recipients should take precautions to pre-
vent vector (including mosquito) -borne dis-
eases. These include avoiding going out during
peak mosquito feeding times (dawn and dusk)
and using N,N-diethyl-meta-toluamide–contain-
ing insect repellants (grade 1, level A).
19. LT recipients should undertake a thorough
review of hobbies to assess potential infectious
disease risks, particularly those associated with
outdoor hobbies (grade 2, level A).
20. All LT recipients should be educated about the
importance of sun avoidance and sun protec-
tion through the use of a sun block with a sun
protection factor of at least 15 and protective
clothing. They should be encouraged to exam-
ine their skin on a regular basis and report any
suspicious or concerning lesions to their physi-
cians (grade 1, level A).
21. Because of the strong association of lung, head,
and neck cancers with smoking, the sustained
cessation of smoking is the most important pre-
ventative intervention (grade 1, level A).
22. For female LT recipients of a child-bearing age,
preconception counseling about contraception
and the risks and outcomes of pregnancy
should start in the pretransplant period and
should be reinforced after transplantation
(grade 1, level A).
BONE HEALTH
Bone loss and fracturing are seen with 2 distinct
phases after LT. In the first 4 postoperative months,
there is accelerated bone loss in almost all liver recipi-
ents, regardless of the pretransplant bone mineral
density (BMD), that is consistent with the effects of
corticosteroids and possibly CNIs.12 After the first 4
postoperative months with normal allograft function,
bone metabolism improves, and in the osteopenic
patient, there will be a gain in bone mass over the
next postoperative years with a gradual reduction in
the incidence of fractures.12,13 In patients with preex-
isting osteopenia or pretransplant fracturing, this
early, rapid bone loss results in a high susceptibility
to fracturing, mainly at sites of trabecular bone (verte-
brae and ribs), especially in the first year after LT, but
there is a smaller but steady cumulative increase in
fracturing.
Table 6 outlines the evaluation of the metabolic
bone status of LT recipients with osteopenia. In the
early years after LT, BMD should be measured annu-
ally in osteopenic patients and every 2 to 3 years in
patients with normal BMD. Later screening depends
on risk factors.
In order to diminish factors that promote bone loss,
glucocorticoids should be reduced or discontinued as
soon as possible after LT. Calcium supplements are
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recommended for all LT recipients with (or at risk of)
osteopenia, and all patients should receive 1000 to
1200 mg of elemental calcium daily to optimize bone
remodeling and mineralization. Vitamin D levels
should be maintained at a serum level of at least 30
ng/mL, and most LT patients will require supplemen-
tation (generally 400-1000 IU/day). The serum levels
of 25-hydroxyvitamin D must be checked to assess
the adequacy of replacement, even with supplementa-
tion, and should be rechecked annually or more fre-
quently if a deficiency is diagnosed. Many issues with
regard to bisphosphonate therapy for LT recipients
remain to be defined: the optimal duration of therapy,
the optimal doses of bisphosphonates, whether oral or
intravenous therapy is better, and the LT population
most likely to benefit. Despite these caveats, we sug-
gest that bisphosphonate therapy should be consid-
ered in the following circumstances:
• T-score less than 2.5 or atraumatic fractures.
• T-score between 1.5 and 2.5 and other risk
factors.
Oral alendronate at 70 mg weekly is an appropriate
starting point, although other oral agents may, how-
ever, be equally efficacious. If oral therapy is not toler-
ated, intravenous zolendronic acid or ibandronate can
be used. The optimal duration of therapy is unknown,
although oral alendronate has been given with good
effect for 10 years for postmenopausal osteoporosis.
Hormone replacement therapy is an alternative in
postmenopausal women.
Recommendations
23. In the first 5 years after transplantation,
screening by BMD should be done yearly for
osteopenic patients and every 2 to 3 years for
patients with normal BMD; thereafter, screen-
ing depends on the progression of BMD and on
risk factors (grade 2, level B).
24. If osteopenic bone disease is confirmed or if
atraumatic fractures are present, then patients
should be assessed for risk factors for bone
loss; in particular, this should include an
assessment of calcium intake and 25-hydroxy-
vitamin D levels, an evaluation of gonadal and
thyroid function, a full medication history, and
thoracolumbar radiography (grade 1, level A).
25. The osteopenic LT recipient should perform reg-
ular weight-bearing exercise and receive cal-
cium and vitamin D supplements (grade 1, level
A).
26. Bisphosphonate therapy should be considered
in LT recipients with osteoporosis or recent
fractures (grade 1, level A).
SYSTEMIC DISEASE
Kidney Disease
The majority of LT recipients who survive the first 6
months develop chronic kidney disease (CKD).6 Pre-
dialysis CKD prevalence rates in this population range
from 30% to 80%. The wide range of reported inciden-
ces is partly due to the different thresholds used to
define CKD and the various durations of posttrans-
plant observation. The cumulative risk of ESRD that
requires maintenance dialysis therapy or kidney
transplantation is 5% to 8% during the first 10 years
after LT.6,14,15 Furthermore, 1.0% of all kidney trans-
plants currently in the United States are undertaken
for LT recipients who subsequently developed
ESRD.16
The etiology of CKD in the LT population is multi-
factorial (Table 2) and includes chronic exposure to
CNIs, hypertension, DM, obesity, atherosclerosis, hy-
perlipidemia, chronic HCV infection, pretransplant re-
nal dysfunction, and perioperative acute kidney
injury. CKD is associated with a 4.48 relative risk of
death more than 1 year after LT in comparison with
recipients without CKD.6,17
A serum creatinine elevation is a late and insensi-
tive indicator of CKD in this population. An estimating
equation that has been shown to have reasonable pre-
cision should be routinely used. Both the 4-variable
Modification of Diet in Renal Disease equation and
the Chronic Kidney Disease Epidemiology Collabora-
tion formula are superior to serum creatinine alone
and 24-hour urinary creatinine clearance in estimat-
ing renal function.18,19 Increased proteinuria (spot
protein-to-creatinine ratio > 0.3) may be absent even
in the presence of advanced CKD because of the anti-
proteinuric effect of CNIs. Proteinuria is best assessed
by the measurement of the concentration ratio of pro-
tein to creatinine in a spot urine specimen.20
Aggressive blood pressure control and the use of
agents that block the renin-angiotensin-aldosterone
system are key foundations of CKD treatment in the
nontransplant population and would be expected to
have beneficial effects in LT recipients. A reduction in
the dosage or a complete withdrawal of CNIs several
months to years after LT is a common practice aimed
at ameliorating the progression of CKD. These renal-
sparing maintenance protocols typically rely on
TABLE 6. Evaluation of the Metabolic Bone Status of
the LT Recipient With Osteopenia
Assessment of bone pain or fractures
Dietary intake of protein and calcium
Serum calcium, phosphorus, and parathormone
levels
25-hydroxyvitamin D level
24-hour urinary calcium (200-300 mg/day)*
Gonadal status: free testosterone (males) or meno-
pausal status (females)
Thyroid function
BMD: lumbar spine and hips
Spinal radiographs (thoracolumbar)
*If it is necessary to confirm a positive calcium balance.
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sirolimus or everolimus, often in combination with
mycophenolate, to prevent acute rejection; others use
steroids and mycophenolate or azathioprine.21-24 Re-
nal function is more likely to be preserved if CNI with-
drawal is instituted when the estimated glomerular fil-
tration rate is between 40 and 50 mL/minute/1.73
m2.25 LT recipients with ESRD who subsequently
receive a living or deceased kidney transplant have a
44% to 60% reduction in long-term mortality in com-
parison with their dialysis-treated counterparts.26,27
Recommendations
27. Monitoring of renal function in LT recipients for
the detection and management of CKD should
use an estimating equation to evaluate the glo-
merular filtration rate (grade 1, level B).
28. Urinary protein quantification using the con-
centration ratio of protein to creatinine in a
spot urine specimen should be evaluated at
least once yearly (grade 1, level B).
29. The reduction or withdrawal of CNI-associated
immunosuppression is an appropriate response
to the development of CKD in LT recipients
(grade 1, level A).
30. Kidney transplantation from deceased or living
donors is beneficial in improving survival and
should be considered the optimal therapy for LT
recipients who develop ESRD (grade 1, level A).
Metabolic Syndrome
The clinical features of metabolic syndrome, either
alone or in combination, contribute to post-LT morbid-
ity and mortality. The clinical factors related to LT that
exacerbate metabolic syndrome are shown in Table 7.
DM
The spectrum of hyperglycemia after LT includes pre-
existing DM and NODM, some of which is transient in
the perioperative period. Insulin-requiring DM that is
present at the time of transplantation virtually always
persists after LT, and many patients on oral hypogly-
cemic agents need a conversion to insulin early after
LT. In LT recipients followed beyond 1 year, estimates
of the prevalence of NODM vary from 5% to 26%. Dia-
betogenic factors after LT include corticosteroids,
CNIs (tacrolimus more than cyclosporine), HCV infec-
tion, and metabolic syndrome.28-33 NODM tends to
remit over time, especially as corticosteroids are with-
drawn and the tacrolimus dosage is reduced, and
patients may go from insulin therapy to oral hypogly-
cemic agents to diet control only over the years.
Because stringent glycemic control significantly
reduces morbidity and mortality in diabetic patients, it
seems reasonable to assume that LT recipients would
similarly benefit. The goals of the long-term manage-
ment of diabetes after LT are not substantially different
from the goals for nontransplant patients (Table 8).
There is controversy regarding the appropriate target
level of hemoglobin A1c (HbA1c), and consequently,
our recommendation of a threshold of <7.0% rather
than <6.0% reflects the view that the more demanding
standard may confer no additional advantage. When
insulin requirements are low, oral agents may be sub-
stituted if allograft function is normal. Metformin or a
sulfonylurea may be used in LT recipients with normal
renal function, whereas sulfonylureas such as glipizide
and glimepiride are preferable if there is any deteriora-
tion in renal function. The safety of thiazolidinediones
in LT recipients is unproven. Retrospective data sets
and a small prospective study suggest that the conver-
sion of immunosuppression from tacrolimus to cyclo-
sporine improves glycemic control in patients with
established DM and NODM.33
Recommendations
31. The treatment of DM after LT should aim for an
HBA1c target goal of <7.0% with a combination
of lifestyle modifications and pharmacological
agents as appropriate (grade 1, level B).
32. When high-dose corticosteroids are adminis-
tered, insulin therapy is the most effective and
safest agent with which to control hyperglyce-
mia; however, as the interval from LT extends,
patients with NODM may experience a decline
in insulin requirements, and oral hypoglycemic
agents may be appropriate if allograft function
is normal (grade 1, level C).
33. Metformin or sulfonylureas may be used in LT
recipients with normal renal function, whereas
sulfonylureas such as glipizide and glimepiride
are preferable if there is any deterioration of re-
nal function (grade 1, level C).
34. Consideration can be given to the conversion of
immunosuppression from tacrolimus to cyclo-
sporine in LT recipients with poor glycemic con-
trol (grade 2, level B).
TABLE 7. Factors Associated With the Clinical Features of Metabolic Syndrome
Factor Corticosteroids Tacrolimus Cyclosporine Sirolimus Chronic HCV
Abdominal obesity þ    
Dyslipidemia þ þ þ þþþ 
Systemic hypertension þ þþ þþ þ 
Insulin-resistant DM þþþ þþ þ  þþ
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Hypertension
Hypertension in LT recipients increases the risk of
fatal and nonfatal cardiovascular disease events and
CKD.15 Although there are no clinical trials of antihy-
pertensive therapy in LT recipients, it is prudent to
target a blood pressure treatment goal of 130/80 mm
Hg in LT recipients with systemic hypertension.34
For the management of hypertensive LT recipients,
immunosuppression leading to hypertension, such as
CNIs and corticosteroids, should be minimized under
the direction of the transplant center.35 Lifestyle mod-
ifications, including weight loss in overweight recipi-
ents (see the discussion on obesity) and the restriction
of dietary salt intake, are appropriate nonpharmaco-
logical interventions.34 Home measurement of blood
pressure is encouraged. If lifestyle modification and a
reduction of immunosuppression do not achieve the
target blood pressure goal, antihypertensive medica-
tions should be introduced. Calcium channel blockers
such as amlodipine and nifedipine may be more effec-
tive in LT recipients because they counteract the va-
soconstrictive effect of CNIs.36 The non-dihydropyri-
dine calcium channel blockers (verapamil and
diltiazem) should be used with caution because they
may increase the bioavailability of CNIs significantly.
Beta-blockers are equally as effective as calcium
channel blockers in the treatment of hypertension
among LT recipients.36 Angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers, and
direct renin inhibitors should be used as first-line
antihypertensive therapy in LT recipients with DM,
CKD, and/or significant proteinuria. Monitoring of po-
tassium levels is necessary when these drugs are
used in conjunction with CNIs (particularly tacroli-
mus). Because of the increased risk of electrolyte
abnormalities, thiazide or loop diuretics should be
used with caution. The combination of diuretics with
other classes of antihypertensive medication may be
particularly effective in some LT recipients because
diuretics tend to mitigate the volume retention associ-
ated with CNIs and/or advanced CKD that commonly
coexists in hypertensive LT recipients.
Recommendations
35. The treatment of hypertension should aim for a
target goal of 130/80 mm Hg with a combina-
tion of lifestyle modifications and pharmacologi-
cal agents as appropriate (grade 1, level A).
36. Angiotensin-converting enzyme inhibitors, an-
giotensin receptor blockers, and direct renin
inhibitors should be used as first-line antihy-
pertensive therapy in LT recipients with DM,
CKD, and/or significant proteinuria (grade 1,
level A).
Hyperlipidemia
Dyslipidemia occurs in up to 70% of LT recipients (a
prevalence much higher than that before transplanta-
tion) and is a major risk factor for cardiovascular
morbidity and mortality (Table 2).37,38 Although age,
body weight, and genetics have some influence, medi-
cations—especially CNIs, mTOR inhibitors, and gluco-
corticoids—are the major influences on the high prev-
alence of dyslipidemia in LT recipients. Furthermore,
3-hydroxy-3-methyl-glutaryl-coenzyme A reductase
inhibitors and CNIs share metabolic pathways and
have significant drug-drug interactions (Table 4). The
TABLE 8. Long-Term Management of DM (New-Onset or Preexisting) After LT
Intervention Frequency
Diagnosis Fasting plasma glucose Every 3 months in the first year and then annually
Monitoring Self-monitoring of blood glucose Review every 3 months
HbA1c Every 3 months (intervention at 7.0%*)
Diabetic complications Annual screening (retinopathy)
Microalbuminuria Annual screening
Tailoring of immunosuppression
(especially if there is poor control):
discontinuation of steroids and change
from tacrolimus to cyclosporine
Lipid levels Annual evaluation
Treatment For all patients
Dietary and lifestyle modification: exercise and
weight loss (if the patient is obese)
Control of hypertension and dyslipidemia
Depending on glycemic control
Insulin†
Oral agent or agents
Insulin 6 oral agent (if there is poor control)
*This should be interpreted with care for patients with anemia or renal impairment.
†Refer patients to an endocrinologist once insulin is started.
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measurement of blood lipids after a 14-hour fast is
recommended annually for healthy LT recipients. Ta-
ble 9 shows a plan for the stepwise treatment of dys-
lipidemia after LT.
Recommendations
37. The measurement of blood lipids after a 14-
hour fast is recommended annually for healthy
LT recipients. An elevated low-density lipopro-
tein cholesterol level > 100 mg/dL, with or
without hypertriglyceridemia, requires therapy.
If therapeutic lifestyle and dietary changes are
not enough, statin therapy should be intro-
duced. Suboptimal control with statins can be
improved by the addition of ezetimibe (grade 2,
level B).
38. Isolated hypertriglyceridemia is first treated
with omega-3 fatty acids (up to 4 g daily if tol-
erated). If this is not sufficient for control, gem-
fibrozil or fenofibrate can be added, although
patients must be followed carefully for side
effects, especially with the concomitant use of
statins and CNIs (grade 2, level C).
NUTRITION AND OBESITY (BODY MASS
INDEX > 30 kg/m2)
Weight accumulation is common after LT. In American
and European cohorts, approximately 20% of lean
patients become obese (body mass index > 30 kg/m2)
in the first 2 to 3 years after LT; this phenomenon is
driven by the restoration of health and the stimulation
of appetite by medicines such as corticosteroids.39,40
Recommendations
39. All LT patients require ongoing dietary counsel-
ing to avoid obesity (grade 1, level C).
40. Among LT recipients who become severely or
morbidly obese and fail behavioral weight-loss
programs, bariatric surgery may be considered,
although the optimal procedure and its timing
with respect to transplantation remain to be
defined (grade 1, level C).
ONCOLOGY
De Novo Cancer
The incidence of de novo cancer is higher among LT
recipients versus an age- and sex-matched nontrans-
plant control population41 (Table 10). The cumulative
incidence of de novo cancer after LT increases from
3% to 5% at 1 to 3 years to 11% to 20% at 10 years
after LT.42,43 Cutaneous malignancies are the most
common form of malignancy in recipients of solid
organ transplants, but cigarette smokers are at
increased risk of developing lung cancer and oropha-
ryngeal cancer, and the rate of colon cancer is
increased in patients undergoing transplantation for
PSC because of the comorbid risk from inflammatory
bowel disease.42-45 The oncogenic risk due to viral
infections [eg, Epstein-Barr virus (EBV) leading to
PTLD] is discussed in the section on viral infections.
The American Cancer Society guideline on screening
for cervical cancer recommends that women who are
immunosuppressed on account of solid organ trans-
plantation ‘‘may need to be screened more often (than
every 3 to 5 years). They should follow the recommen-
dations of their healthcare team.’’46 Careful prospec-
tive surveillance accompanied by lifestyle modifica-
tions to protect the skin and to quit smoking
improves outcomes for LT recipients.43,44
Recurrent or Persistent Cancer
The proportion of patients undergoing LT for HCC
has increased significantly in the past decade. Rates
of recurrence at 4 years are 10% for patients with
tumors within the Milan criteria and 40% to 60% for
patients with tumors outside the Milan criteria.47 Tu-
mor recurrence reduces long-term survival after LT
TABLE 9. General Plan for the Stepwise Management
of Dyslipidemia
Elevated low-density lipoprotein cholesterol level >
100 mg/dL (with or without elevated triglycerides)
1. Therapeutic lifestyle and dietary changes
2. Statins
3. Addition of ezetimibe
Hypertriglyceridemia with normal cholesterol
1. Fish oil at 1000 mg twice daily to 4 g daily if
tolerated
2. Fibric acid derivatives
Refractory hyperlipidemia: consider changes in
immunosuppression
1. Conversion of cyclosporine to tacrolimus
2. CNI reduction (eg, add mycophenolate mofetil)
3. Discontinuation of sirolimus
TABLE 10. Relative Risks of De Novo Malignancies in
LT Recipients Versus a Sex- and Age-Matched
Population
Malignancy Relative Risk
Skin cancers
Squamous and basal
cell carcinoma
20%-70%
Melanoma 2%-5% (estimate)
Lymphoma 10%-30%
Oropharyngeal cancer,
including esophageal
cancer
3%-14%
(as high as 25%
if the prior diagnosis
was alcoholic cirrhosis)
Lung cancer 1.7%-2.5%
Colorectal cancer 25%-30% if ulcerative
colitis is present
Kidney cancer 5%-30%
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for HCC. Accumulating data suggest that once post-
operative healing is complete, the substitution of siro-
limus for a CNI reduces the risk of recurrence of
HCC.48
Guidelines for surveillance after LT, including the
choice of the surveillance method, the intervals
between surveillance tests, and the duration of sur-
veillance, have not been established for patients
undergoing transplantation for known HCC or for
patients with incidental HCC found in the explanted
liver.47 A reasonable plan is for the patient to undergo
abdominal and chest computed tomography every 6
months for 3 years after LT. The serial measurement
of alpha-fetoprotein is a useful adjunct for patients
who had an elevated alpha-fetoprotein level before
transplantation or ablation therapy. Any suspicious
lesion discovered on surveillance should be character-
ized fully, and biopsy should be included when the di-
agnosis is in doubt. Ablation with radiofrequency is
the best treatment for small solitary recurrences.
Recommendations
41. All LT recipients should see a dermatologist af-
ter transplantation to assess cutaneous lesions,
with at least an annual evaluation by a derma-
tologist 5 years or more after transplantation
(grade 1, level A).
42. Patients with PSC and inflammatory bowel dis-
ease or other established risk factors for colo-
rectal cancer should undergo an annual
screening colonoscopy with biopsies. Colec-
tomy, including continence-preserving pouch
operations, should be considered when colonic
biopsy reveals moderate or severe dysplasia
(grade 1, level B).
43. For patients without prior HCC who develop
recurrent cirrhosis of the allograft, surveillance
for de novo HCC should be undertaken with ab-
dominal imaging every 6 to 12 months (grade 1,
level A).
44. An immunosuppressant regimen that includes
sirolimus (started several weeks after trans-
plantation) should be considered for patients
undergoing transplantation for HCC (grade 2,
level B).
45. Resection or ablation is usually the treatment
of choice for a solitary extrahepatic metastasis
or an intrahepatic recurrence of HCC (grade 1,
level B).
REPRODUCTIVE HEALTH
Menstruation and probably fertility return by 10
months in 90% of premenopausal females after suc-
cessful LT and in some patients as early as 1 to 2
months.49-51 Free testosterone levels increase in
males after LT, but the recovery of male gonadal func-
tion is often incomplete. LT has limited efficacy for
curing pretransplant sexual dysfunction in either men
or women.52 Sildenafil is beneficial and well tolerated
by male LT recipients with erectile dysfunction.53
Pregnancy in the LT recipient has risks to both the
mother and the fetus.51,54 Although the numbers of
pregnancies reported are relatively small, pregnancies
completing the first trimester successfully generally
proceed to a live birth, although there is a higher inci-
dence of prematurity (29%-50%) and low birth weight
(17%-57%).51,54 Neonatal deaths or birth defects are
not more frequent in comparison with the general
population (except when the mother is on mTOR
inhibitors).55,56 The maternal risks include hyperten-
sion and pre-eclampsia, which occur more commonly
in comparison with the general population.57 Mater-
nal deaths following pregnancy in LT recipients are
rare and occur at a rate similar to that in the general
population. The National Transplant Pregnancy Regis-
try guidelines51 recommend the female LT recipients
postpone conception until
• At least 1 year after LT.
• Allograft function is stable.
• Medical comorbidities such as diabetes and
hypertension are well controlled.
• Immunosuppression is at a low maintenance
level.
The choice of immunosuppression should be made
before conception. All immunosuppressive drugs
cross the placenta and enter the fetal circulation with
resulting concerns about teratogenicity and fetal loss.
Table 11 shows the Food and Drug Administration
(FDA) safety categories for drugs in pregnancy. Gener-
ally, CNIs (class C drugs), prednisone (class B), and
azathioprine (class D) appear to be safe.54 The newer
agents should be avoided if possible; in the National
Transplant Pregnancy Registry,51 more structural
abnormalities have been seen in babies born to
TABLE 11. FDA Safety Categories for Drugs Used
During Pregnancy
A. Controlled studies in women fail to demonstrate a
risk to the fetus in the first trimester (and there is no
evidence of risk in later trimesters), and the possibil-
ity of fetal harm appears remote.
B. Animal reproduction studies have not demon-
strated fetal risk, but there are no controlled studies
in pregnant women, OR animal studies have shown
an adverse effect that has not been confirmed in con-
trolled studies in women in the first trimester.
C. Animal studies have revealed adverse effects on
the fetus, and there are no controlled studies in
women, OR studies in women and animals are not
available. Give the drug only if the potential benefit
justifies the risk.
D. There is positive evidence of human fetal risk, but
benefits from use in pregnant women may be accept-
able despite the risk.
X. A definitive fetal risk exists, and the drug is con-
traindicated in women who are or may become
pregnant.
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mothers on mTOR inhibitors or mycophenolic acid,
especially when they are used in early pregnancy.55,56
European guidelines for renal recipients advise dis-
continuing mTOR inhibitors at least 6 weeks before
conception.58
An early diagnosis of pregnancy is desirable to
maximize positive pregnancy outcomes. Immunosup-
pression should be maintained during pregnancy to
avoid rejection, and drug levels of CNIs should be
monitored with dose adjustments for the increasing
blood volume during the second half of pregnancy.59
Allograft function and CNI serum levels should be
monitored frequently until delivery. Screening the
mother for urinary tract infections, the presence of
cytomegalovirus (CMV) and toxoplasmosis, hyperten-
sion, gestational diabetes, and pre-eclampsia, along
with serial assessments of fetal growth, is
mandatory.
Allograft dysfunction during pregnancy warrants
appropriate investigation, including liver biopsy in
selected patients, to assess for rejection. The pregnant
patient with acute cellular rejection is treated in the
same manner as the nonpregnant patient. There are
no contraindications to vaginal delivery.
Allograft function and drug levels should be
checked weekly for at least 1 month after birth or
until the patient is stable, especially if adjustments
were made during the pregnancy or allograft dysfunc-
tion arose late in the pregnancy. Although the known
benefits of breast feeding probably outweigh the theo-
retical risks, no definitive recommendations regarding
breast feeding can be made. Low levels of immuno-
suppressive drugs may be found in breast milk. Con-
traception with whatever method is favored by the LT
recipient should start before sexual activity is
resumed.
Recommendations
46. Pregnancy in an LT recipient should be managed
by a high-risk obstetrician in coordination with
the transplant hepatologist (grade 1, level C).
47. Pregnancy should be delayed for 1 year after LT
and occur at a time with good, stable allograft
function, with maintenance immunosuppres-
sion, and with good control of any medical com-
plications such as hypertension and diabetes
(grade 1, level B).
48. The ideal immunosuppression for pregnancy is
tacrolimus monotherapy, which should be
maintained at therapeutic levels throughout
pregnancy; cyclosporine, azathioprine, and
prednisone may also be used if they are neces-
sary (grade 1, level B).
49. Allograft function and CNI serum levels are
monitored every 4 weeks until 32 weeks, then
every 2 weeks, and then weekly until delivery
(grade 1, level B).
50. Contraception should begin before the resump-
tion of sexual activity, although no particular
form of contraception can be recommended
over another (grade 2, level B).
INFECTIOUS DISEASE
General Overview
The interval from the third to sixth month after LT is a
high-risk period because of the occurrence of infec-
tions with opportunistic pathogens: herpes viruses
(especially CMV, herpes zoster and simplex, and EBV),
fungi (including Aspergillus and Cryptococcus), and
unusual bacterial infections such as Nocardia, Listeria,
and mycobacteria. The implementation of prophylactic
antimicrobials, the avoidance of high-risk exposures,
and the minimization of immunosuppression may
reduce the occurrence of these pathogens.60 After the
sixth posttransplant month, the risk of infection is
lower, and this is related to the reduction of immuno-
suppression. From 3 to 24 months after LT, in the
standard-risk LT recipient (ie, no augmented immuno-
suppression or specific environmental exposures), the
most common infections are intra-abdominal or in the
lower respiratory tract or infections by community-
acquired pathogens such as enteric gram-negative
infections, Streptococcus pneumonia, and respiratory
viruses.60 Rare infections related to immunosuppres-
sion, such as the reactivation of John Cunningham
polyomavirus resulting in progressive multifocal leu-
koencephalopathy, are not reviewed here. Table 12
shows an outline of prophylactic strategies for counter-
ing common organisms that affect LT recipients. Table
4 outlines the drug-drug interactions involving anti-
infectives and immunosuppressive agents.
Recommendations
51. An assessment for infections following LT
should take into account the intensity of immu-
nosuppression, the timing of the presentation,
the environmental and donor exposures, the
recipient’s history of both symptomatic and
latent infections, and the utilization of prophy-
lactic antimicrobials and immunizations (grade
1, level A).
52. Attention should be paid to potential drug
interactions when new antimicrobial therapies
are initiated (grade 1, level A).
CMV
CMV remains the most significant opportunistic
pathogen affecting LT recipients and produces diverse
clinical manifestations and significant morbidity and
mortality.61,62 The most common clinical syndromes
include viremia, bone marrow suppression, and
involvement of the gastrointestinal tract and liver.
Risk factors for CMV61,62 include the following:
• CMV-seropositive donor organ (especially in the
absence of prior immunity, ie, a CMV-seronega-
tive recipient).
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• Augmented immunosuppression (especially with
the use of anti-lymphocyte antibodies or high-
dose mycophenolate).
• Allograft rejection.
• Coinfection with other immunomodulating
viruses (eg, human herpesviruses 6 and 7), bacte-
ria, or fungi.
The diagnosis of CMV includes the detection of the
virus in conjunction with the recognition of an asso-
ciated clinical syndrome.61,62 Patients who are not
receiving prophylactic antivirals and are at increased
risk for CMV (because of a CMV-seropositive donor
and/or treatment for rejection) may be monitored for
evidence of infection with nucleic acid testing (poly-
merase chain reaction). Typically, CMV occurs in the
first 3 months in the absence of prophylaxis. How-
ever, because of current standard prophylactic strat-
egies, it now presents later after the cessation of pro-
phylaxis, frequently in the first year or after the
augmentation of immunosuppression. Currently, rou-
tine screening for CMV is not recommended while
patients are receiving prophylaxis. After the comple-
tion of prophylaxis, some centers have adopted a
hybrid approach using nucleic acid testing to screen
for infections in the highest risk patients. However,
there is no clear evidence to support the screening of
asymptomatic patients at this time. The detection of
viremia by either nucleic acid testing (polymerase
chain reaction) or the pp65 antigenemia assay is rec-
ommended for the diagnosis of an active CMV infec-
tion.61,62 Typically, the viral load correlates with the
severity of disease and can be a marker of the
response to therapy. Some individuals, especially
those with hepatitis or gastrointestinal disease, may
exhibit low-level or no viremia despite a symptomatic
infection and require tissue biopsy for the diagnosis
of CMV disease to be made. Finally, some LT recipi-
ents exhibit low-level viremia without symptomatic
disease.
The treatment of CMV should be started whenever
recipients are symptomatic, have a tissue injury, or
have persistent or increasing viremia.61,63,64 All LT
recipients with a symptomatic CMV infection and/or
end organ disease should receive antiviral therapy
and have their immunosuppression reduced until vi-
remia and all symptoms have resolved. Patients with
low-level viremia (this is difficult to define because of
laboratory variability) should be assessed for symp-
toms and, if they are asymptomatic, should have
immunosuppression reduction as tolerated and viral
load testing repeated. If the viral load rises and/or
symptoms develop, treatment should be
administered.
Options for antiviral treatment include intravenous
ganciclovir (5 mg/kg twice daily adjusted for renal
impairment) and oral valganciclovir (900 mg twice
TABLE 12. Prophylactic Strategies for Common Organisms That Affect LT Recipients
Organism Agent/Dosage Duration Comments
CMV
Donor-positive/
recipient-negative
Valganciclovir (900 mg/day) or
intravenous ganciclovir (5 mg/kg/day)
3-6 months Valganciclovir is
not FDA-approved
for LT. Prolonged-duration
regimens are effective in
kidney transplantation.
Recipient-positive Valganciclovir (900 mg/day),
intravenous ganciclovir,
or weekly CMV viral load monitoring and
antiviral initiation when viremia is identified
3 months Valganciclovir is not
FDA-approved for LT.
Fungi Fluconazole (100-400 mg daily),
itraconazole (200 mg twice daily),
caspofungin (50 mg daily), or liposomal
amphotericin (1 mg/kg/day)
4-6 weeks?
(optimal duration
unknown)
Reserve for high-risk
individuals (pretransplant
fungal colonization,
renal replacement therapy,
massive transfusion,
choledochojejunostomy,
reoperation,
retransplantation,
or hepatic iron overload).
P. jirovecii (P. carinii) Trimethoprim sulfamethoxazole
(single strength daily
or double strength 3 times per week),
dapsone (100 mg daily),
or atovaquone (1500 mg daily)
6-12 months
(optimal duration
unknown)
A longer duration of
therapy should be
considered for patients
on augmented
immunosuppression.
Lifelong therapy should
be considered for
HIV-infected recipients.
TB (latent infection) Isoniazid (300 mg daily) 9 months Monitor for hepatotoxicity.
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daily adjusted for renal impairment) for mild to mod-
erate disease if no significant gastrointestinal
involvement is assumed (note: valganciclovir is not
approved for use in LT). For those patients with
more severe disease or gastrointestinal involvement,
intravenous ganciclovir is preferable. A minimum of
2 weeks of treatment is recommended for those
patients with rapid resolution of symptoms, but
treatment should be continued until there is com-
plete resolution of both symptoms and viremia.
Whenever possible, a reduction in immunosuppres-
sion should be combined with antiviral therapy.
Ganciclovir resistance is uncommon in solid organ
transplant recipients.
Recommendations
53 High-risk recipients (CMV-seronegative recipi-
ents of CMV-seropositive donor organs) should
receive prophylaxis with ganciclovir or valganci-
clovir for a minimum of 3 months after trans-
plantation (grade 1, level B).
54. The treatment of LT recipients with CMV should
be maintained until viremia and all symptoms
have resolved (grade 2, level B).
55. Prophylaxis against CMV should be resumed
whenever LT recipients receive anti-lymphocyte
therapy for the treatment of rejection and should
be continued for 1 to 3 months after the treat-
ment of rejection (grade 2, level B).
56. The treatment of a CMV infection should consist
of the following:
a. Consideration of immunosuppression reduction.
b. High-dose intravenous ganciclovir or oral val-
ganciclovir in individuals with mild to moderate
disease without gastrointestinal involvement or
a reduced capacity for absorption.
c. A minimum of 2 weeks of treatment. Treat-
ment should be continued to complete the re-
solution of all symptoms and viremia (grade
1, level A).
57. Resistant virus should be suspected in patients
with a history of prolonged ganciclovir or valgan-
ciclovir exposure who have a persistent or pro-
gressive infection despite treatment with high-
dose intravenous ganciclovir (grade 1, level A).
In such instances, genotypic assays should be
performed, and consideration should be given to
the initiation of foscarnet with or in substitution
for ganciclovir (grade 1, level B).
EBV/PTLD
EBV-associated PTLD is an uncommon but serious
complication of LT with an incidence in adults of
0.9% to 2.9%.64,65 Risk factors include a primary EBV
infection, CMV donor-recipient mismatch or CMV dis-
ease, and augmented immunosuppression, especially
with anti-lymphocyte antibodies.66 It is uncertain
whether the etiology of liver disease influences the de-
velopment of PTLD.67,68 The association of PTLD with
EBV infection is variable in adult LT recipients; later
onset PTLD is less likely to be EBV-associated.64,67,68
Manifestations of PTLD include lymphadenopathy,
cytopenias, unexplained fever, and disturbances of
the gastrointestinal tract, lungs, spleen, and central
nervous system.
The diagnosis of PTLD requires a high index of
suspicion and should be considered in high-risk
individuals who present with undiagnosed fever or
unexplained lymphadenopathy or cytopenias.66–69
Radiographic studies can identify sites of involvement,
especially when pulmonary or intra-abdominal sites
are involved. The detection of EBV viremia with
nucleic acid testing is not diagnostic of EBV-associ-
ated PTLD.
The initial treatment of PTLD is a reduction of
immunosuppression.65–69 If there is no clinical
response within 2 to 4 weeks, additional therapies,
including anti-CD20 humanized chimeric monoclonal
antibodies (rituximab), surgical therapy, radiation
therapy, and cytotoxic chemotherapy, may be
required. The addition of antiviral therapy has not
been proven to affect outcomes.
Recommendations
58. PTLD should be considered in LT recipients
(especially high-risk individuals) who present
with unexplained fever, lymphadenopathy, or
cytopenias (grade 1, level A).
59. Although EBV may be associated with the de-
velopment of PTLD, the detection of EBV vire-
mia is not diagnostic for PTLD; a
histopathological diagnosis is required (grade 1,
level A).
Fungal Infections
Risk factors for fungal infections after LT include pre-
operative fungal colonization, massive transfusion
requirements (>40 U of blood products), choledocho-
jejunostomy, reoperation, retransplantation, hepatic
iron overload, renal replacement therapy, and
extended intervals of intensive care immediately
before LT. The epidemiology of invasive fungal infec-
tions in LT recipients has shifted over the past 2 dec-
ades, with a decrease in Candida infections and an
increasing incidence of Aspergillus infections.70 The
recognition of an invasive fungal infection after 90
days is challenging. Blood cultures are relatively
insensitive for the diagnosis of many fungal infections,
including Candida species, for which the (1,3)-b-D-
glucan test is an inconsistent measure.71,72 Aspergil-
lus is especially difficult to diagnose with noninvasive
testing.70 The sensitivity and specificity of galacto-
mannan in either blood or bronchoalveolar lavage
from LT recipients with presumed pulmonary asper-
gillosis are variable.72-74 Serum and cerebrospinal
cryptococcal antigen testing is a sensitive tool for the
rapid diagnosis of cryptococcal infections in organ
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transplant recipients.75 The isolation of Cryptococcus
from a site other than cerebrospinal fluid should
prompt lumbar puncture to rule out central nervous
system involvement. Urinary histoplasmosis and Blas-
tomyces antigens have been useful for the diagnosis
of disseminated histoplasmosis and blastomycosis,
respectively.76,77
The treatment of fungal infections includes antifun-
gal drug therapy as well as a reduction of immuno-
suppressive therapy. The choice of antifungal agents
varies with the pathogen and the site of involvement,
as shown in Table 13.
Recommendations
60 The diagnosis of fungal infections may require
diagnostic biopsy for pathological and microbio-
logical confirmation (grade 1, level A).
a. Blood cultures are most helpful for the diag-
nosis of Candida bloodstream infections
(class 1, level B) and Blastomyces (grade 1,
level B).
b. Cryptococcal antigen testing of cerebrospinal
fluid or blood is most helpful for the diagnosis
of Cryptococcus (grade 1, level B).
c. Urinary histoplasmosis and Blastomyces anti-
gens are useful for the diagnosis of dissemi-
nated histoplasmosis and blastomycosis,
respectively (grade 1, level B).
61. A cautious reduction of immunosuppression
should be initiated to prevent immune reconsti-
tution syndrome, especially for cryptococcal
infections (grade 1, level B).
Pneumocystis jirovecii (Pneumocystis carinii)
P. jirovecii (formerly called P. carinii) is an uncommon
pathogen in LT recipients, primarily because of the
widespread use of antimicrobial prophylaxis after
LT.78 Pneumocystis should be suspected in individu-
als presenting with respiratory symptoms, hypoxemia
(often exacerbated by exercise), and fever.78 Classic
radiographic findings include bilateral interstitial infil-
trates. The diagnosis is confirmed by the identification
of the organism by a cytological examination of
induced sputum or bronchoalveolar lavage fluid.
High-dose trimethoprim-sulfamethoxazole (adminis-
tered orally or intravenously at 15-20 mg/kg/day in
divided doses and adjusted for renal dysfunction) is
the drug of choice.78 Corticosteroids (40-60 mg of
prednisone or its equivalent) should be used in con-
junction with antimicrobial therapy for patients with
significant hypoxia (partial pressure of arterial oxygen
TABLE 13. Preferred Antifungal Agents
Organism/Disease Agent Comments
Candida Triazoles (fluconazole, Itraconazole, voriconazole,
and posaconazole), echinocandins
(eg, caspofungin, micafungin,
and anidulafungin), or amphotericin
B and analogues
Candida glabrata and Candida krusei
may be resistant to triazoles
(especially fluconazole).
Differentiate colonization
from infection. The duration
of therapy varies with the
site of infection.
Aspergillus Triazoles (voriconazole is the
drug of choice; itraconazole
and posaconazole are also active), caspofungin,
or amphotericin B and analogues
The duration of therapy is dependent
on the response to therapy.
Cryptococcus Amphotericin B and analogues in combination with
5-flucytosine for 2 weeks followed by fluconazole
(400-800 mg/day) for 8 weeks and then fluconazole
(200 mg/day) for 6-12 months
Cautiously reduce
immunosuppression. Patients
with isolated pulmonary disease
may not require amphotericin
induction. The duration varies
with the response.
Blastomycosis Itraconazole (200 mg twice daily) for mild to moderate
disease and amphotericin B and analogues
for severe disease
The standard duration
is 6-12 months.
Coccidiomycosis Fluconazole (400-800 mg daily), itraconazole
(200 mg twice daily), or amphotericin B and analogues
Amphotericin should be used for
more severe disease and should
be considered when there is
central nervous system involvement.
The standard duration is 6-12 months
with chronic suppression thereafter.
Histoplasmosis Itraconazole (200 mg twice daily) or amphotericin
B and analogues for 2 weeks of
induction followed by fluconazole
The minimum duration is 12 months.
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< 70 mm Hg on room air). The minimal duration of
antimicrobial therapy is 14 days, but more severe
infections may merit longer courses of treatment.
Recommendations
62. All LT recipients should receive prophylaxis
against P. jirovecii with trimethoprim-sulphame-
thoxazole (single strength daily or double
strength 3 times per week) for a minimum of 6 to
12 months after transplantation (grade 1, level
A). Atovaquone and dapsone are the preferred
alternatives for patients who are intolerant of tri-
methoprim sulfamethoxazole (grade 1, level B).
63. Trimethoprim-sulphamethoxazole is the drug of
choice for the treatment of P. jirovecii pneumo-
nia. Intravenous pentamidine is the preferred
alternative for patients intolerant of trimetho-
prim-sulphamethoxazole with more severe
infections (grade 1, level A).
64. Patients with clinical signs and symptoms or
radiological features suggestive of P. jirovecii
pneumonia should undergo sputum sampling
or bronchoalveolar lavage with a cytological ex-
amination using a silver or Giemsa stain, poly-
merase chain reaction, or a specific antibody
stain to identify the organism (grade 1, level A).
Tuberculosis (TB)
Several risk factors for the development of sympto-
matic TB after LT have been identified: a prior infec-
tion with TB; intensified immunosuppression (espe-
cially anti–T lymphocyte therapies); DM; and
coinfections with CMV, mycoses, P. jirovecii, and
Nocardia.79 Donor-derived TB is rare. The diagnosis
of TB may be confounded by an increased incidence
of atypical presentations (especially extrapulmonary
infections involving diverse organs and locations).80,81
Standard antituberculous regimens for drug-suscepti-
ble isolates include 2 months of 4-drug therapy with
isoniazid, rifampin, ethambutol, and pyrazinamide
followed by an additional 4 months of isoniazid and
rifampin. Patients with central nervous system
involvement, bone and joint disease, or disseminated
infections may warrant longer courses of treatment.80-
82 The use of anti-TB agents in LT recipients is com-
plicated by hepatotoxicity and by the significant drug-
drug interactions with immunosuppressive agents,
which lead to the potential for hepatotoxicity associ-
ated with antitubercular chemotherapy. Because of
the risk of a marked reduction in CNI and mTOR in-
hibitor levels with rifampin coadministration, the
doses of CNIs will need to be increased 2- to 5-fold at
the initiation of treatment.79 Rifabutin may be substi-
tuted for rifampin to reduce the impact on drug levels,
or non–rifampin-containing regimens can be consid-
ered, although the duration of treatment will need to
be extended.
Recommendations
65. The treatment of active TB should include the
initiation of a 4-drug regimen using isoniazid,
rifampin, pyrazinamide, and ethambutol (under
the assumption of susceptible TB) with adjust-
ments in accordance with subsequent culture
results. This may be tapered to 2 drugs (isonia-
zid and rifampin) after 2 months (under the
assumption of no resistance) and continued for
a minimum of 4 additional months (grade 1,
level B).
66. Close monitoring for rejection and hepatotoxic-
ity is imperative while LT recipients receive
anti-TB therapy (grade 1, level A).
Human Immunodeficiency Virus (HIV)
HIV-infected patients with well-controlled infections
have undergone transplantation with success,
although aggressive HCV recurrence has been prob-
lematic in LT recipients coinfected with HCV.83 HIV-
infected patients maintained on highly active antire-
troviral therapy (HAART) after transplantation do not
experience an increase in opportunistic infections.
The use of HAART in LT recipients is complicated by
significant drug-drug interactions with immunosup-
pressive agents, which lead to a risk of cyclosporine
or tacrolimus toxicity or inadequate immunosuppres-
sion.84 LT recipients with HCV-HIV coinfections have
a higher frequency and severity of acute cellular rejec-
tion.85 The CNI doses and the frequency of their
administration need to be reduced markedly in LT
recipients receiving HAART containing protease inhib-
itors.83,84 In contrast, those receiving nonnucleoside
reverse transcriptase inhibitors (especially efavirenz)
will require higher doses of CNIs.
Recommendations
67. HIV-infected LT recipients receiving HAART
require frequent monitoring of CNI levels
because of the significant interaction between
antiretrovirals and CNIs (grade 1, level A).
68. HIV-infected LT recipients receiving HAART
should be followed with scheduled HIV viral
loads and T lymphocyte subset counts (grade 1,
level A).
69. Standard prophylaxis for CMV is recommended
for HIV-infected LT recipients receiving HAART,
and lifelong Pneumocystis pneumonia prophy-
laxis is the norm (grade 1, level A).
70. Standard HIV-specific prophylaxis for low CD4
counts should be used (grade 1, level A).
IMMUNIZATIONS
Appropriate advice regarding vaccination after LT has
been reviewed by Danzinger-Isakov et al.86 and is also
reviewed in Table 14. LT recipients should avoid live
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virus vaccines because of concerns about the dissemi-
nation of infections. Vaccine-related rejection has not
been associated with immunization following LT.
Recommendations
71. All LT recipients should receive an annual
influenza vaccination (grade 1, level B).
72. All LT recipients should avoid live virus vac-
cines (grade 1, level A).
73. Re-immunization is indicated for some vac-
cines, notably the influenza vaccine (annually)
and the pneumococcal vaccine (every 3-5 years;
no class or level provided). (grade 1, level A).
VIRAL HEPATITIS
Hepatitis B Virus (HBV)
Chronic HBV accounts for less than 10% of trans-
plants performed in the United States and Western
Europe, whereas in Asia, it is the most common indi-
cation for LT. Importantly, in the last decade, there
has been a shift in the primary indication for LT
among HBV-infected patients, with HCC more fre-
quent than end-stage liver disease.87 This trend
reflects the efficacy of antiviral therapy in preventing
complications of cirrhosis as well as the increased pri-
oritization of HCC for LT.
The survival for patients undergoing transplantation
for HBV is excellent, and HBV ranks among the best
of all indications for LT. The improvements in patient
and graft survival evident over the past 10 to 15 years
reflect the advances in therapeutics to prevent and
control HBV infections after LT. The combination of
hepatitis B immune globulin (HBIG) and nucleos(t)ide
analogues can prevent recurrent infections in almost
all HBV-infected LT patients.88-91 The combination of
HBIG and nucleos(t)ide analogues is superior to HBIG
alone. The individualization of prophylactic combina-
tion therapy can be undertaken on the basis of pre-
transplant clinical and virological characteristics. For
example, low-dose intramuscular HBIG is much less
expensive and avoids painful side effects associated
with intravenous HBIG. The discontinuation of HBIG
is generally reserved for patients at low risk for HBV
recurrence.92
A recurrent infection is manifest with persistently
detectable HBV DNA and hepatitis B surface antigen
in serum and is usually due to a failure of prophylac-
tic therapy. Liver biopsy is useful for assessing the se-
verity of HBV recurrence and the progression of fibro-
sis. Fibrosing cholestatic HBV is a unique histological
variant observed in LT recipients and is characterized
by high intrahepatic levels of HBV DNA, hepatocyte
ballooning with cholestasis, and a paucity of inflam-
matory cells.93 This represents the most severe pre-
sentation of recurrent disease and is rarely seen in
the current era of prophylactic therapy.
Recommendations
74. Long-term prophylactic therapy using a combi-
nation of antiviral agents and low-dose HBIG
on demand or at fixed intervals can effectively
prevent HBV recurrence rates in 90% of trans-
plant recipients (grade 1, level B).
75. In patients with low or undetectable HBV DNA
levels before transplantation and an absence of
high-risk factors for recurrence, HBIG can be
discontinued, and long-term treatment with
antivirals (single or in combination) can be
used as an alternative prophylactic strategy
(grade 2, level B).
76. Lifelong antiviral therapy should be used to
treat patients with recurrent HBV infections.
Combination antiviral therapy is superior to
monotherapy when drugs with a low genetic
barrier to resistance are used, whereas the dis-
continuation of HBIG is generally reserved for
patients at low risk for HBV recurrence (grade 1,
level B).
TABLE 14. Recommended Immunizations for Adult LT
Recipients
Before Transplantation After Transplantation
Influenza Influenza
Pneumococcus* Pneumococcus*
Hepatitis A virus†
HBV†
Tetanus/diphtheria/
acellular pertussis‡
Human papilloma virus§
Varicella virusk
Zoster¶
NOTE: Transplant recipients may also receive the
following vaccines safely: the meningococcal vaccine, the
inactivated Salmonella Typhi vaccine (Typhim Vi
intramuscular vaccine), the Japanese encephalitis
vaccine, and the Vibrio cholera vaccine. Live virus
vaccines should be avoided after transplantation.
*The pneumococcal vaccine should be repeated every 3 to
5 years after the initial administration.
†Ideally, hepatitis A virus and HBV immunizations should
be administered before transplantation. There are no
guidelines regarding posttransplant immunization,
although these vaccines are safe after transplantation.
HBV antibody levels should be measured annually after
transplantation, with boosters considered for waning
immunity.
‡The tetanus/diphtheria/acellular pertussis vaccine can
also be safely administered after transplantation.
§This vaccine is indicated for females up to the age of 26
years. It can be safely administered after transplantation.
kThis vaccine can be administered safely before
transplantation to nonimmune individuals. It should not
be administered after transplantation.
¶This vaccine is indicated for individuals who are 60
years old or older. No studies have been conducted in
patients with cirrhosis. It should not be administered
after transplantation.
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77. Retransplantation for recurrent HBV is appro-
priate when treatment strategies to prevent or
treat recurrent HBV disease are available (grade
1, level C).
HCV
Recurrent HCV infection is invariable among patients
who are viremic at LT, the majority of whom will have
histological evidence of recurrent hepatitis within the
first year after LT.94 Although the progression of fibro-
sis in HCV-infected LT recipients is highly variable, in
the absence of antiviral therapy, the median time to
the development of cirrhosis is 8 to 10 years, whereas
an estimated 30% will develop cirrhosis within 5 years
of LT.95 The risk of decompensation is 15% to 30%
within the first year of the onset of cirrhosis, and the
mortality risk is 40% to 55% within 6 to 12 months of
the decompensating event. Recurrent HCV cirrhosis is
the most frequent cause of graft loss in this popula-
tion.96 Patient survival and graft survival are reduced
in HCV-infected patients versus HCV-negative
patients, with a 5-year patient survival rate of approx-
imately 70%.97,98
HCV-infected recipients have higher rates of graft
loss when the allograft is from an older donor.99 There
is a higher risk of cirrhosis when HCV-infected LT
recipients develop acute rejection that requires treat-
ment or comorbid CMV hepatitis.100 Although recur-
rent HCV is more likely the longer the interval from
LT, in practice, it is often difficult to distinguish
between the histopathological appearances of a recur-
rent HCV infection and acute cellular rejection. The
impact of immunosuppressives on the progression of
HCV is poorly understood, although some data sug-
gest that anti-lymphocyte agents promote HCV-asso-
ciated liver injury. Post-LT diabetes, insulin resist-
ance, and (more inconsistently) steatosis have been
associated with a higher risk of rapid progression to
advanced fibrosis.
Posttransplant antiviral therapy is generally re-
served for those showing evidence of progressive dis-
ease, which is manifested by the presence of moderate
to severe necroinflammation or mild to moderate fi-
brosis, although this paradigm will change with more
efficacious and less toxic antiviral therapy.100 The pri-
mary goal of post-LT antiviral therapy is the achieve-
ment of sustained viral clearance because this virolog-
ical outcome is associated with fibrosis stabilization
or regression and improved graft survival.101 The ini-
tiation of antiviral therapy is recommended when sig-
nificant histological disease is present, although this
paradigm would change with more efficacious and
less toxic antiviral therapy. The pooled estimated rate
of acute graft rejection occurring in patients receiving
peginterferon and ribavirin is 5%, which is not signifi-
cantly higher than the rate in untreated controls.102
However, alloimmune or plasma cell hepatitis, charac-
terized histologically by an inflammatory infiltrate
with abundant plasma cells in the setting of increased
liver enzymes, has been described during antiviral
therapy.103 This is most likely a variant of allograft
rejection and responds to the discontinuation of inter-
feron and the amplification of immunosuppression in
most cases. With the recent approval of the first-gen-
eration protease inhibitors, telaprevir and boceprevir,
it is anticipated that triple therapy (peginterferon, rib-
avirin, and either telaprevir or boceprevir) will evolve
into the new standard of care over the next few years
for LT recipients infected with genotype 1 virus. Cur-
rently, neither protease inhibitor is approved for use
in transplant recipients. There are significant drug-
drug interactions between HCV protease inhibitors
and CNIs and probably mTOR inhibitors as well. The
prospect of interferon-free protocols is also of great in-
terest because of the possibility that interferon indu-
ces an alloimmune response in some LT recipients.
Recommendations
78. Liver biopsy is useful in monitoring disease se-
verity and progression and in distinguishing
recurrent HCV disease from other causes of
liver enzyme elevations (grade 1, level C).
79. Prophylactic antiviral therapy has no current
role in the management of HCV disease (grade
1, level A).
80. Moderate acute rejection should be treated with
increased maintenance immunosuppression
and corticosteroid boluses, whereas lympho-
cyte-depleting drugs should be avoided (grade
1, level B).
81. Antiviral therapy is indicated for significant his-
tological disease: grade 3 or higher inflamma-
tory activity and/or stage 2 or higher fibrosis
(on a scale of 4) or cholestatic hepatitis. Pegin-
terferon and ribavirin are the current drugs of
choice. The risks and benefits of triple therapy
with protease inhibitors are to be determined.
The goal of antiviral therapy is the achievement
of a sustained virological response, and this
confers a survival benefit (grade 1, class B).
82. Retransplantation for recurrent HCV disease
should be considered selectively (grade 2, level B).
PBC
PBC is an excellent indication for liver replacement
with the one of the highest rates of risk-adjusted out-
come.104 Immunological abnormalities (eg, elevated
immunoglobulins and autoantibodies) persist after
transplantation. Recipients remain at risk for associ-
ated conditions, such as sicca syndrome, osteoporo-
sis, and thyroid disease, so screening should be
included in the follow-up.
Recurrent PBC is diagnosed by liver histology:
recurrent disease may occur in the presence of nor-
mal liver tests, and neither the presence nor the titer
of anti-mitochondrial antibodies correlates with the
presence or degree of recurrence.105,106 The reported
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incidence of recurrent PBC varies from 4% to 33%
(the average is 18%).104 Although the use of cyclospo-
rine is associated with less severe recurrence and cor-
ticosteroids may be associated with less recurrence,
there are insufficient data to recommend a preferred
immunosuppressive regimen.106 The impact of the re-
currence of PBC on graft function and survival is min-
imal for the first decade after transplantation, with
end-stage disease affecting less than 5%. There is no
evidence that routine protocol biopsy in PBC LT recip-
ients will improve outcomes. Ursodeoxycholic acid at
a dose of 10 to 15 mg/kg/day is associated with an
improvement in liver tests, but there are no data to
show benefits in patient or graft survival.104
Recommendations
83. PBC LT recipients should be routinely monitored
for associated autoimmune diseases (eg, thyroid
disease) and bone density (grade 2, level B).
84. For those with histological evidence of recurrent
disease, treatment with ursodeoxycholic acid at
10 to 15 mg/kg/day (grade 2, level B) may be
considered, and although its use is associated
with the improvement of liver tests, no impact
on graft survival has been documented (grade 2,
level B). There is no indication for offering pro-
phylaxis with ursodeoxycholic acid to patients
with normal liver histology (grade 2, level B).
PSC
PSC is an excellent indication for LT with good long-
term outcomes. Recipients with a Roux loop are at
increased risk for recurrent cholangitis; those few
who have a retained native bile duct are at risk for
cholangiocarcinoma. In patients with chronic ulcera-
tive colitis (CUC), colitis may improve or deteriorate
after transplantation.107 PSC LT recipients with CUC
are at greater risk of developing colonic polyps and
cancer and should have an annual colonoscopy. There
is no evidence for the optimal screening approach in
PSC LT recipients without CUC, but many advocate
an annual colonoscopy in this group also.
Recurrent PSC is seen in up to 50% of patients at 5
years, with graft loss due to recurrent PSC occurring in
as many as 25% of patients with recurrent PSC.108 The
diagnosis of recurrent PSC is based on a combination
of biochemical, radiological, and histological findings
in particular, multiple nonanastomotic biliary stric-
tures or characteristic liver histology, and the exclusion
of other causes such as infections or ischemia second-
ary to thrombosis of the hepatic artery. Risk factors for
recurrent PSC include male sex, an intact colon before
or during transplantation, a history of steroid-resistant
or recurrent rejection, active CUC after transplanta-
tion, the use of anti-lymphocyte therapy for the treat-
ment of cellular rejection, sex mismatch between the
donor and the recipient, CMV infection, and the pres-
ence of specific HLA haplotypes (eg, HLA-DRB1*08). In
PSC recipients with CUC, prophylactic colectomy does
not reduce the risk of recurrent PSC. There is insuffi-
cient evidence to support maintaining corticosteroids
in patients undergoing transplantation for PSC.
Recommendation
85. Although there are few data on prevention, it is
recommended that those patients grafted for
PSC in the presence of CUC have an annual colo-
noscopy with mucosal biopsy (grade 2, level B).
AIH
Outcomes after transplantation for AIH are good.
Patients should be closely monitored for evidence of
recurrence via liver tests every 6 months.109 Protocol
liver biopsy should be considered at 5 yearly intervals.
The reported outcome rates for recurrent AIH are
highly variable. Although the majority of patients with
putative recurrent AIH will respond clinically, serolog-
ically, and histologically to increased immunosup-
pression, some will progress to end-stage graft failure
and may require retransplantation.
Recommendation
86. Although there is no evidence for recommend-
ing a particular immunosuppressive regimen in
patients undergoing transplantation for AIH, it
is prudent to maintain patients on long-term,
low-dose corticosteroids in addition to routine
immunosuppression (with attention to main-
taining bone health; grade 2, level B).
ALCOHOLIC LIVER DISEASE (ALD)
Although ALD patients selected for LT have a survival
rate similar to that of recipients without ALD,110 post-
LT mortality is increased in recipients with comorbid
ALD and HCV. There is a wide variation in the reported
rates of alcohol relapse by ALD patients after LT (10%-
90%). The best prospective study showed that 80% of
ALD LT recipients either did not drink or consumed
only small amounts occasionally in the first 5 years.111
Conversely, in the remaining 20%, there were various
patterns of harmful drinking. Anecdotal reports suggest
that patients who relapse to harmful drinking are at
risk for alcoholic hepatitis, delirium tremens, alcoholic
pancreatitis, and reduced survival.110 Furthermore, the
causes of death for the patients who returned to heavy
consumption of alcohol tended to be liver-related,
whereas abstinent ALD patients died of cardiovascular
disease and malignant tumors. The stratification of car-
diovascular deaths and new-onset cancers of the aero-
digestive tract in patients undergoing LT for ALD sug-
gests a causal linkage with cigarette smoking.17
Recommendations
87. All patients with a prior diagnosis of ALD
should be encouraged to remain abstinent from
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alcohol (grade 1, level B).
88. Patients should be encouraged to enter therapy
or counseling if they relapse into alcohol use
(grade 1, level C).
89. All patients with a prior diagnosis of ALD who
are users of tobacco should be encouraged to
undertake smoking cessation (grade 1, level B).
90. Careful attention should be given to the risk of
cardiovascular disease and/or new-onset can-
cers of the aerodigestive tract, especially in cig-
arette smokers (grade 1, level A).
NONALCOHOLIC STEATOHEPATITIS
(NASH)/NONALCOHOLIC FATTY LIVER
DISEASE (NAFLD)
It appears that NASH-associated cirrhosis is the
fourth most common cause of liver failure leading to
LT in the United States, and it is predicted that by
2020-2030, NASH-associated cirrhosis will become
the most common indication for LT.112 NAFLD and
NASH, both recurrent and de novo, are common after
LT.37,113-115 Immunosuppressant agents may contrib-
ute to metabolic syndrome: corticosteroids and tacro-
limus promote diabetes, sirolimus promotes hyperlip-
idemia, and cyclosporine and tacrolimus promote
systemic hypertension. Risk factors for post-LT
NASH/NAFLD are familiar as the hallmarks of meta-
bolic syndrome: body mass index before and after LT,
DM, systemic hypertension, hyperlipidemia, and stea-
tosis on an allograft biopsy sample. Among patients
who undergo LT on account of NASH-associated or
cryptogenic cirrhosis, 50% to 70% will gain excessive
weight in 1 year.115
New-onset or recurrent NAFLD/NASH may present
with elevated liver aminotransferases. Distinguishing
NAFLD/NASH from other causes of elevated liver tests
in the post-LT patient requires liver biopsy. NAFLD/
NASH arising in the liver allograft, whether new-onset
or recurrent, may lead to fibrosis.115 Cirrhosis associ-
ated with fat accumulation in the allograft is uncom-
mon in the first 5 years after LT. No effect on patient
or graft survival has been observed among LT recipi-
ents with new-onset or re-emergent NAFLD/NASH,
although most studies have been short in duration.
Although there are no good data to support one
immunosuppressive regimen over another in patients
who undergo transplantation for NASH/cirrhosis or
cryptogenic cirrhosis, minimizing corticosteroids
appears prudent. Renal impairment is more common
in those undergoing transplantation for NAFLD.
Recommendations
91. The confirmation of recurrent or de novo NAFLD,
the recognition of fibrosis, and the exclusion of
alternate causes of elevated liver chemistry tests
require liver biopsy (grade 1, level B).
92. No specific recommendations regarding the pre-
vention or treatment of NAFLD or NASH in LT
recipients can be made other than general rec-
ommendations to avoid excessive gains in body
weight and control hypertension and diabetes
(grade 1, level C).
LATE SURGICAL COMPLICATIONS
Hepatic artery stenosis, biliary cast syndrome, and
bilomas have already been discussed with respect to
abnormal liver tests. Incisional hernia is a common
late complication after LT. Postoperative weight gain
exacerbates the risk.
Recommendation
93. LT recipients with an incisional hernia should
be instructed to recognize incarcerated hernias
and advised to seek immediate medical assis-
tance (grade 1, level B).
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